Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents
NCT02993237Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide and darunavir + cobicistat in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of Acceptability of Swallowing Fixed-Dose Combination (FDC) Tablets at Day 1. Started Jan 2017; status: completed.
02
Drugs
tenofovir alafenamidedarunavir + cobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02993237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993237.